Why is Telix Pharmaceuticals Limited (ASX:TLX) up ~10%?
Telix Pharmaceuticals (ASX: TLX) is trading ~10% higher today driven by another important regulatory milestone for the $5.9bn radiopharmaceutical company. The US FDA has approved Telix’s Pixclara (floretyrosine F18), providing the company with another commercial product in the world’s largest healthcare market.
Pixclara is the first FDA-approved FET-PET imaging agent for glioma, a form of brain cancer, and is indicated for differentiating recurrent or progressive disease from treatment-related changes in adults and paediatric patients aged one month and older.
The approval addresses a significant unmet clinical need. Following treatment for glioma, conventional imaging can struggle to distinguish between genuine tumour progression and changes caused by radiation or other therapies. FET-PET imaging provides physicians with additional information to help determine whether the cancer is progressing, potentially allowing for more accurate and timely treatment decisions.
- Importantly for Telix, FDA approval moves Pixclara from being a promising pipeline asset towards a commercial opportunity and further broadens the company beyond its established prostate-cancer imaging franchise.
- It also reinforces TLX’s strategy of building an integrated radiopharmaceutical business spanning diagnostic imaging and targeted therapies across several cancer indications.
The positive read-through has been reflected in analyst commentary, with Jefferies lifting its TLX price target by 2.4% to $30 following the announcement. Broader sentiment towards radiopharmaceuticals was also supportive, with reports that GE HealthCare is in advanced discussions to acquire Sofie Biosciences for around US$1bn, providing another reminder of the strategic value being placed on assets across the sector.
- Today’s strong rally is all about the Pixclara approval removing an important regulatory hurdle and improving visibility around another potential earnings stream.
MM’s take: The FDA approval is another important box ticked for Telix and strengthens an increasingly diversified radiopharmaceutical platform. After the stock’s powerful recovery from its February lows, expectations have clearly risen, but successful commercialisation of Pixclara provides another potential leg to the company’s longer-term growth story.
- We like TLX as an aggressive play below $18.
